SEC Comment Letter 0000000000-24-010040 to Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd.
Date: Sept. 5, 2024 · CIK: 0001536196 · Accession: 0000000000-24-010040
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281872
Letter
September 5, 2024 Motti Farbstein Chief Executive Officer Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel Re:Can-Fite BioPharma Ltd. Registration Statement on Form F-1 Filed August 30, 2024 File No. 333-281872 Dear Motti Farbstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
September 5, 2024
Motti Farbstein
Chief Executive Officer
Can-Fite BioPharma Ltd.
26 Ben Gurion Street
Ramat Gan 5257346 Israel
Re:Can-Fite BioPharma Ltd.
Registration Statement on Form F-1
Filed August 30, 2024
File No. 333-281872
Dear Motti Farbstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.